Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] EXAMINE: targeting risk and treatment in diabetes – Authors’ reply

Giuseppe Derosa and Pamela Maffioli question whether heart failure or mortality outcomes in the EXAMINE1 trial differed according to sex or dose of alogliptin. Post-hoc analyses of these factors have shown no significant heterogeneity between men and women or among the 25 mg, 12·5 mg, and 6·25 mg dose cohorts (dose adjustments were prespecified and based on levels of the estimated glomerular filtration rates) for alogliptin and placebo on these outcomes.

email